Ligand Pharmaceuticals Inc Dossier
Outlook & Key Dates
Estimates, guidance, catalysts, and upcoming events
Analyst Estimates Learn more →
5-Yr Fwd EPS Growth
21.4%projected annual EPS growth
Analyst Coverage
11analysts covering
FY Revenue (est.)
$290.6Mnext fiscal year
FY EPS (est.)
$9.32next fiscal year
Reporting Calendar
| Event | Expected Date |
|---|---|
| 2026 Investor Day in New York City | 8 Dec 2026 |
Monitoring Framework
Key Performance Indicators
Total Revenue Annually268.1MTarget: 270000000 to 310000000
Royalty Revenue Annually161MTarget: 225000000 to 250000000
Captisol Material Sales Annually40.2MTarget: 35000000 to 40000000
Core Adjusted Earnings per Diluted Share Annually813.0%Target: 8.50 to 9.50
Watch Items
- XOMA Royalty Acquisition IntegrationTrigger: Closing of transaction expected in Q3 2026Action: Monitor regulatory approvals, XOMA stockholder vote, and immediate accretion to adjusted EPS.
- Filspari Commercial PerformanceTrigger: U.S. net product sales growth and patient start formsAction: Track Travere Therapeutics' quarterly updates on IgAN and FSGS patient uptake to project royalty streams.
- Ohtuvayre and Capvaxive Royalty ContributionsTrigger: Market launch and commercial adoption by partnersAction: Evaluate partner sales reports to verify royalty growth trajectory.
Research as of 19 Jun 2026